Mereo BioPharma Group (NASDAQ:MREO) Stock Keeps “Buy” Rating at BTIG Research

Posted by Francis Steltz on Nov 10th, 2026

Mereo BioPharma Group (NASDAQ:MREO – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at BTIG Research in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $1.00 price target on the stock. BTIG Research‘s price target points to a potential upside of 238.87% from the stock’s current price.

MREO has been the subject of several other reports. JPMorgan Chase & Co. downgraded Mereo BioPharma Group from a “neutral” rating to an “underweight” rating in a research note on Wednesday, August 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Mereo BioPharma Group in a research note on Tuesday, September 29th. Finally, Needham & Company LLC reissued a “buy” rating on shares of Mereo BioPharma Group in a report on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Mereo BioPharma Group presently has an average rating of “Hold” and an average target price of $1.67.

Read Our Latest Research Report on MREO

Mereo BioPharma Group Stock Performance

Shares of MREO stock opened at $0.30 on Tuesday. The firm has a fifty day simple moving average of $0.31 and a 200-day simple moving average of $0.33. Mereo BioPharma Group has a twelve month low of $0.20 and a twelve month high of $2.37.

Mereo BioPharma Group (NASDAQ:MREO – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01). The firm had revenue of $0.80 million for the quarter, compared to analyst estimates of $0.01 million. As a group, equities analysts predict that Mereo BioPharma Group will post -0.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its holdings in Mereo BioPharma Group by 32,048.5% during the 1st quarter. Bank of America Corp DE now owns 8,195,287 shares of the company’s stock worth $2,704,000 after acquiring an additional 8,169,795 shares in the last quarter. Defilade Capital Management L.P. bought a new position in shares of Mereo BioPharma Group during the first quarter worth about $2,494,000. EcoR1 Capital LLC lifted its position in shares of Mereo BioPharma Group by 70.2% during the first quarter. EcoR1 Capital LLC now owns 13,368,855 shares of the company’s stock worth $4,412,000 after purchasing an additional 5,512,389 shares during the last quarter. Finally, Forefront Analytics LLC grew its stake in Mereo BioPharma Group by 302.2% in the first quarter. Forefront Analytics LLC now owns 127,778 shares of the company’s stock worth $42,000 after purchasing an additional 96,010 shares in the last quarter. 62.83% of the stock is currently owned by institutional investors.

About Mereo BioPharma Group

(Get Free Report)

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases and oncology. The company’s research programs are intended to address conditions with significant unmet medical needs, using biologic and small-molecule drug candidates.

Mereo’s lead program is setrusumab, an investigational monoclonal antibody designed to inhibit sclerostin and stimulate bone formation. The therapy is being developed for osteogenesis imperfecta, a rare genetic disorder characterized by fragile bones, through a collaboration with Ultragenyx Pharmaceutical.